The present study describes the design and evaluation of the drug jusvinza for treating rheumatoid arthritis and other inflammatory diseases. Jusvinza’s active component is an altered peptide ligand (APL) derived from the 60 kDa human cellular stress protein (HSP60). This protein is an autoantigen implicated in the pathogenesis of several autoimmune diseases. Starting from HSP60, a T-cell epitope was predicted using bioinformatics tools. The corresponding peptide was modified to alter its interaction with the HLA class II molecule, thereby modifying its immunogenic properties. Preclinical studies and clinical research results in rheumatoid arthritis have demonstrated that jusvinza exhibits anti-inflammatory activity and can induce mechanisms associated with restoring peripheral tolerance and immunological homeostasis. Additionally, jusvinza was repurposed to treat COVID-19 patients displaying signs of hyperinflammation, contributing to their recovery. Overall, jusvinza represents an interesting therapeutic approach for various inflammation-related diseases, including autoimmune disease, COVID-19, atherosclerosis and diabetes.